A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC

被引：2
|
作者：
Bergstrom, Donald [1 ]
Bodyak, Natalya [1 ]
Yurkovetskiy, Alex [1 ]
Poling, Laura [1 ]
Yin, Mao [1 ]
Protopopova, Marina [1 ]
Devit, Mike [1 ]
Qin, Liuliang [1 ]
Gumerov, Dmitry [1 ]
Ter-Ovanesyan, Elena [1 ]
Mosher, Rebecca [1 ]
Lowinger, Timothy [1 ]
机构：
[1] Mersana Therapeut, Cambridge, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Novel Therapies; Antibody-drug conjugate; Adenocarcinoma; Targeted chemotherapy;
D O I：
10.1016/j.jtho.2016.11.450
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA09.10
引用
收藏
页码：S396 / S397
页数：2
相关论文
共 50 条
  • [21] The antibody-drug conjugate D3-GPC2-PBD potently eradicates neuroblastoma patient-derived xenografts
    Bosse, Kristopher R.
    Zhu, Zhongyu
    Lane, Maria
    Martinez, Daniel
    DeLong, John
    Zhelev, Doncho V.
    Feng, Yang
    Wang, Yanping
    Hwang, Jennifer
    Dimitrov, Dimiter S.
    Maris, John
    CANCER RESEARCH, 2018, 78 (13)
  • [22] A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions
    Damelin, Marc Isaac
    Bankovich, Alex
    Bernstein, Jeff
    Lucas, Justin
    Chen, Liang
    Williams, Sam
    Park, Albert
    Aguilar, Jorge
    Ernstoff, Elana
    Charati, Manoj
    Dushin, Russell
    Jackson-Fisher, Amy
    Aujay, Monette
    Lee, Christina
    Ramoth, Hanna
    Milton, Milly
    Hampl, Johannes
    Lazetic, Sasha
    Pulito, Virginia
    Armellino, Douglas
    Rosfjord, Edward
    Guffroy, Magali
    Falahatpisheh, Hadi
    King, Lindsay
    Barletta, Frank
    Stull, Robert
    Pysz, Marybeth
    Escarpe, Paul
    Liu, David
    Foord, Orit
    Gibson, Brenda
    Powell, Eric
    O'Donnell, Christopher
    Xin, Xiaohua
    Gerber, Hans Peter
    Sapra, Puja
    Dylla, Scott
    CANCER RESEARCH, 2016, 76
  • [23] PATIENT-DERIVED TUMOR XENOGRAFT MODELS: THE NEXT-GENERATION OF PRECLINICAL MODELS FOR ONCOLOGY DRUG DEVELOPMENT
    Eckhardt, S. G.
    Tan, A. C.
    Pitts, T.
    Leong, S.
    Arcaroli, J.
    Messersmith, W. A.
    Jimeno, A.
    Weekes, C. D.
    Tentler, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 17 - 17
  • [24] A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
    Do, Myan
    Wu, Christina C. N.
    Sonavane, Pooja R.
    Juarez, Edwin F.
    Adams, Stephen R.
    Ross, Jason
    Baena, Alessandra Rodriguez Y.
    Patel, Charmi
    Mesirov, Jill P.
    Carson, Dennis A.
    Advani, Sunil J.
    Willert, Karl
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (01) : 113 - 124
  • [25] Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived Xenografts
    Abu-Yousif, Adnan O.
    Cvet, Donna
    Gallery, Melissa
    Bannerman, Bret M.
    Ganno, Michelle L.
    Smith, Michael D.
    Lai, Katharine C.
    Keating, Thomas A.
    Stringer, Bradley
    Kamali, Afrand
    Eng, Kurt
    Koseoglu, Secil
    Zhu, Andy
    Xia, Cindy Q.
    Landen, Melissa Saylor
    Borland, Maria
    Robertson, Robbie
    Bolleddula, Jayaprakasam
    Qian, Mark G.
    Fretland, Jennifer
    Veiby, O. Petter
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) : 2079 - 2088
  • [26] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
    Hamilton, E. P.
    Barve, M. A.
    Tolcher, A. W.
    Buscema, J.
    Papadopoulos, K. P.
    Zarwan, C.
    Anderson, C. K.
    Doroshow, D.
    Wang, D.
    Huebner, D.
    Jansen, V. M.
    Jarlenski, D.
    Mosher, R.
    Kaufman, J.
    Moore, K. N.
    Richardson, D. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
  • [27] Patient-derived xenograft (PDX) models of NSCLC reflect clinical drug responses and predict effective treatments for patients
    Ciznadija, Daniel
    Astaturov, Igor
    Cheng, Haiying
    Peled, Nir
    Jaskowiak, Jennifer
    Davies, Angela
    Sidransky, David
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [28] MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models.
    Cho, Song
    Zammarchi, Francesca
    Monks, Noel R.
    Vashisht, Kapil
    Tammali, Ravinder
    Schifferli, Kevin
    Strout, Patrick
    King, Wanda
    Dacosta, Karma
    Fleming, Ryan
    Williams, David G.
    Havenith, Karin
    Hinrichs, Mary Jane Masson
    Chivers, Simon
    Dimasi, Nazzareno
    Howard, Phil W.
    Hartley, John A.
    Coats, Steve
    Herbst, Ronald
    van Berkel, Patrick H.
    Tice, David A.
    CANCER RESEARCH, 2018, 78 (16) : 25 - 25
  • [29] Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
    Lock, Richard B.
    Evans, Kathryn
    Randall, Joanna
    Erickson, Stephen W.
    Earley, Eric J.
    Neuhauser, Steven
    Stearns, Tim
    Philip, Vivek
    Teicher, Beverly A.
    Watkins, Krystal
    Sloss, Callum M.
    Zweidler-McKay, Patrick A.
    Smith, Malcolm A.
    BLOOD, 2022, 140 : 8983 - 8984
  • [30] A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC)
    Burris, Howard A.
    Gordon, Michael S.
    Gerber, David E.
    Spigel, David R.
    Mendelson, David S.
    Schiller, Joan H.
    Wang, Yulei
    Choi, Younleong
    Kahn, Robert S.
    Wood, Katie
    Maslyar, Daniel J.
    Infante, Jeffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345